A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Parsaclisib in Participants With Normal Renal Function and Participants With Renal Impairment

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Aug 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Parsaclisib (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Myelofibrosis; Solid tumours
Focus Pharmacokinetics
Sponsors Incyte Corporation

16 Aug 2022 Status changed from recruiting to completed.
03 Jun 2022 Planned End Date changed from 30 Jun 2022 to 30 Jul 2022.
03 Jun 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Jul 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com